دورية أكاديمية
The implication of serum HLA-G in angiogenesis of multiple myeloma.
| العنوان: | The implication of serum HLA-G in angiogenesis of multiple myeloma. |
|---|---|
| المؤلفون: | Wang C; Department of Laboratory Medicine, MacKay Memorial Hospital, New Taipei, 25160, Taiwan., Su NW; Department of Hematology, MacKay Memorial Hospital, Taipei, 10449, Taiwan.; Nursing, and Management, MacKay Junior College of Medicine, New Taipei, 25245, Taiwan., Hsu K; Nursing, and Management, MacKay Junior College of Medicine, New Taipei, 25245, Taiwan.; Institute of Biomedical Sciences, MacKay Medical College, New Taipei City, 25245, Taiwan.; Department of Medical Research, Mackay Memorial Hospital, New Taipei City, 25160, Taiwan., Kao CW; Department of Hematology, GCRC Laboratory, Mackay Memorial Hospital, New Taipei City, 25160, Taiwan., Chang MC; Department of Hematology, MacKay Memorial Hospital, Taipei, 10449, Taiwan.; Department of Medicine, MacKay Medical College, New Taipei City, 25245, Taiwan., Chang YF; Department of Hematology, MacKay Memorial Hospital, Taipei, 10449, Taiwan.; Department of Hematology, GCRC Laboratory, Mackay Memorial Hospital, New Taipei City, 25160, Taiwan., Lim KH; Department of Hematology, MacKay Memorial Hospital, Taipei, 10449, Taiwan.; Department of Hematology, GCRC Laboratory, Mackay Memorial Hospital, New Taipei City, 25160, Taiwan.; Department of Medicine, MacKay Medical College, New Taipei City, 25245, Taiwan., Chiang YH; Department of Hematology, MacKay Memorial Hospital, Taipei, 10449, Taiwan.; Department of Hematology, GCRC Laboratory, Mackay Memorial Hospital, New Taipei City, 25160, Taiwan.; Department of Medicine, MacKay Medical College, New Taipei City, 25245, Taiwan., Chang YC; Department of Hematology, MacKay Memorial Hospital, Taipei, 10449, Taiwan.; Department of Hematology, GCRC Laboratory, Mackay Memorial Hospital, New Taipei City, 25160, Taiwan.; Department of Medicine, MacKay Medical College, New Taipei City, 25245, Taiwan., Sung MT; Department of Hematology, MacKay Memorial Hospital, Taipei, 10449, Taiwan., Wu HH; Medical Laboratory Science and Biotechnology, Taipei Medical University, Taipei, 110, Taiwan., Chen CG; Department of Hematology, MacKay Memorial Hospital, Taipei, 10449, Taiwan. calebchen52@hotmail.com.; Nursing, and Management, MacKay Junior College of Medicine, New Taipei, 25245, Taiwan. calebchen52@hotmail.com.; Department of Hematology, GCRC Laboratory, Mackay Memorial Hospital, New Taipei City, 25160, Taiwan. calebchen52@hotmail.com.; Institute of Molecular Medicine, National Tsing-Hua University, Hsin-Chu, Taiwan. calebchen52@hotmail.com. |
| المصدر: | Molecular medicine (Cambridge, Mass.) [Mol Med] 2024 Jun 14; Vol. 30 (1), pp. 86. Date of Electronic Publication: 2024 Jun 14. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: BioMed Central Country of Publication: England NLM ID: 9501023 Publication Model: Electronic Cited Medium: Internet ISSN: 1528-3658 (Electronic) Linking ISSN: 10761551 NLM ISO Abbreviation: Mol Med Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2018- : [London, United Kingdom] : BioMed Central Original Publication: Cambridge, Mass. : Blackwell Scientific Publications, c1994- |
| مواضيع طبية MeSH: | Multiple Myeloma*/blood , Multiple Myeloma*/metabolism , Multiple Myeloma*/pathology , Neovascularization, Pathologic*/metabolism , HLA-G Antigens*/blood , HLA-G Antigens*/metabolism , Interleukin-6*/blood , Interleukin-6*/metabolism, Humans ; Animals ; Mice ; Male ; Female ; Vascular Endothelial Growth Factor A/metabolism ; Vascular Endothelial Growth Factor A/blood ; Middle Aged ; Cell Line, Tumor ; Hypoxia-Inducible Factor 1, alpha Subunit/metabolism ; Aged ; Disease Models, Animal ; Angiogenesis |
| مستخلص: | Background: Despite the advances of therapies, multiple myeloma (MM) remains an incurable hematological cancer that most patients experience relapse. Tumor angiogenesis is strongly correlated with cancer relapse. Human leukocyte antigen G (HLA-G) has been known as a molecule to suppress angiogenesis. We aimed to investigate whether soluble HLA-G (sHLA-G) was involved in the relapse of MM. Methods: We first investigated the dynamics of serum sHLA-G, vascular endothelial growth factor (VEGF) and interleukin 6 (IL-6) in 57 successfully treated MM patients undergoing remission and relapse. The interactions among these angiogenesis-related targets (sHLA-G, VEGF and IL-6) were examined in vitro. Their expression at different oxygen concentrations was investigated using a xenograft animal model by intra-bone marrow and skin grafts with myeloma cells. Results: We found that HLA-G protein degradation augmented angiogenesis. Soluble HLA-G directly inhibited vasculature formation in vitro. Mechanistically, HLA-G expression was regulated by hypoxia-inducible factor-1α (HIF-1α) in MM cells under hypoxia. We thus developed two mouse models of myeloma xenografts in intra-bone marrow (BM) and underneath the skin, and found a strong correlation between HLA-G and HIF-1α expressions in hypoxic BM, but not in oxygenated tissues. Yet when stimulated with IL-6, both HLA-G and HIF-1α could be targeted to ubiquitin-mediated degradation via PARKIN. Conclusion: These results highlight the importance of sHLA-G in angiogenesis at different phases of multiple myeloma. The experimental evidence that sHLA-G as an angiogenesis suppressor in MM may be useful for future development of novel therapies to prevent relapse. (© 2024. The Author(s).) |
| References: | Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230) J Am Heart Assoc. 2020 Dec;9(23):e017820. (PMID: 33225820) Nature. 2009 Apr 9;458(7239):732-6. (PMID: 19360080) Annu Rev Pathol. 2017 Jan 24;12:187-215. (PMID: 27959627) J Immunol Res. 2014;2014:359748. (PMID: 24800261) Eur J Haematol. 2013 Feb;90(2):134-41. (PMID: 23210517) Blood. 2004 Apr 15;103(8):3131-7. (PMID: 15070695) Am J Pathol. 2000 Aug;157(2):411-21. (PMID: 10934146) Nat Commun. 2017 Nov 28;8(1):1823. (PMID: 29180628) Genes Dev. 2000 Jan 1;14(1):34-44. (PMID: 10640274) Nature. 1997 Nov 27;390(6658):404-7. (PMID: 9389480) J Clin Oncol. 2005 May 20;23(15):3412-20. (PMID: 15809451) Lancet. 2003 Feb 8;361(9356):489-91. (PMID: 12583950) Cancer Res. 1999 Nov 15;59(22):5830-5. (PMID: 10582706) Am J Clin Pathol. 2007 Dec;128(6):1002-9. (PMID: 18024326) Hum Immunol. 2007 Apr;68(4):277-85. (PMID: 17400064) Thromb Haemost. 2004 Dec;92(6):1438-45. (PMID: 15583754) Leukemia. 2006 Feb;20(2):193-9. (PMID: 16357836) Haematologica. 2010 May;95(5):776-84. (PMID: 20015878) Int J Mol Sci. 2020 Jun 25;21(12):. (PMID: 32630545) Clin Chem. 2005 May;51(5):878-81. (PMID: 15774572) Lancet Oncol. 2014 Nov;15(12):e538-48. (PMID: 25439696) Eur J Cancer. 2006 Jul;42(11):1581-90. (PMID: 16797965) Blood. 2006 Oct 15;108(8):2608-15. (PMID: 16809620) Nature. 2014 Apr 10;508(7495):269-73. (PMID: 24590072) Blood. 2008 Jan 15;111(2):785-9. (PMID: 17942755) Am J Pathol. 2013 Feb;182(2):540-52. (PMID: 23219427) Cell Immunol. 1994 May;155(2):312-22. (PMID: 8181068) PLoS One. 2013 Nov 06;8(11):e79939. (PMID: 24223204) Hum Immunol. 2012 Sep;73(9):946-9. (PMID: 22820627) Leukemia. 2011 Oct;25(10):1533-42. (PMID: 21637285) Trends Cancer. 2021 May;7(5):389-392. (PMID: 33563576) J Clin Invest. 2020 Apr 1;130(4):1565-1575. (PMID: 32149732) J Immunol Res. 2017;2017:4587520. (PMID: 28781970) Front Endocrinol (Lausanne). 2019 Jan 08;9:788. (PMID: 30671025) Leukemia. 2015 Oct;29(10):2033-8. (PMID: 25962523) Expert Opin Drug Discov. 2019 Jul;14(7):667-682. (PMID: 31070059) Annu Rev Biochem. 2009;78:399-434. (PMID: 19489725) Int Rev Immunol. 2021;40(5):330-343. (PMID: 33426980) Cell Death Dis. 2021 Mar 15;12(3):273. (PMID: 33723230) Leukemia. 2006 Sep;20(9):1467-73. (PMID: 16855634) Nature. 2002 Dec 19-26;420(6917):860-7. (PMID: 12490959) Blood. 2011 May 5;117(18):4691-5. (PMID: 21292775) J Cell Biol. 1997 Aug 11;138(3):707-17. (PMID: 9245797) Clin Chem. 2002 Sep;48(9):1437-44. (PMID: 12194920) Clin Cancer Res. 2005 Oct 15;11(20):7297-303. (PMID: 16243800) Leukemia. 2014 May;28(5):1122-8. (PMID: 24157580) J Biol Chem. 1996 Jan 12;271(2):736-41. (PMID: 8557680) J Reprod Immunol. 2007 Dec;76(1-2):17-22. (PMID: 17467060) PLoS One. 2009 Oct 22;4(10):e6913. (PMID: 19847290) N Engl J Med. 2011 Mar 17;364(11):1046-60. (PMID: 21410373) Nature. 2018 Jul;559(7714):410-414. (PMID: 29995846) Oncotarget. 2017 Dec 22;9(5):6536-6549. (PMID: 29464090) Blood. 2001 Jul 15;98(2):428-35. (PMID: 11435313) Nat Rev Mol Cell Biol. 2005 Jan;6(1):9-20. (PMID: 15688063) FASEB J. 2015 Jan;29(1):208-15. (PMID: 25326537) Leuk Res. 2012 Jul;36(7):881-3. (PMID: 22421410) Blood. 2019 Feb 14;133(7):660-675. (PMID: 30587529) Cancer Treat Rev. 2015 Dec;41(10):827-35. (PMID: 26296679) Blood. 2005 Apr 15;105(8):3286-94. (PMID: 15618473) |
| فهرسة مساهمة: | Keywords: Angiogenesis; Human leukocyte antigen G; Hypoxia-inducible factor-1α; Interleukin 6; Multiple myeloma; Vascular endothelial growth factor |
| المشرفين على المادة: | 0 (HLA-G Antigens) 0 (Interleukin-6) 0 (Vascular Endothelial Growth Factor A) 0 (Hypoxia-Inducible Factor 1, alpha Subunit) |
| تواريخ الأحداث: | Date Created: 20240614 Date Completed: 20240615 Latest Revision: 20240718 |
| رمز التحديث: | 20240719 |
| مُعرف محوري في PubMed: | PMC11177474 |
| DOI: | 10.1186/s10020-024-00860-5 |
| PMID: | 38877399 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1528-3658 |
|---|---|
| DOI: | 10.1186/s10020-024-00860-5 |